Transplant Outcomes in High-Risk (Class 3) Patients with Thalassemia Treated with a Modified Protocol Are Equivalent to Low/Intermediate-Risk (Class 1/Class 2) Patients

被引：0

作者：

Gaziev, Javid ^{[1
]}

De Angelis, Gioia ^{[1
]}

Isgro, Antonella ^{[1
]}

Sodani, Pietro ^{[1
]}

Marziali, Marco ^{[1
]}

Paciaroni, Katia ^{[1
]}

Andreani, Marco ^{[1
]}

Testi, Manuela ^{[1
]}

Gallucci, Cristiano ^{[1
]}

Alfieri, Cecilia ^{[1
]}

Ribersani, Michela ^{[1
]}

Troiano, Maria ^{[1
]}

Morrone, Aldo ^{[1
]}

Lucarelli, Guido ^{[1
]}

机构：

[1] Policlin Vergata, Int Ctr Transplantat Thalassemia & Sickle Cell An, Mediterranean Inst Hematol, Rome, Italy

来源：

BLOOD | 2015年 / 126卷 / 23期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[21] Insulin administration may trigger type 1 diabetes in patients with type 2 diabetes having high-risk HLA class II
Makino, H.
Nishida, W.
Nakamura, M.
Yamada, Y.
Chujo, D.
Imagawa, A.
Hanafusa, T.
Takahashi, K.
Suehiro, T.
Watanabe, Y.
Moriyama, H.
Nagata, M.
Yokono, K.
Onuma, H.
Osawa, H.
DIABETOLOGIA, 2009, 52 : S83 - S83
[22] CLINICAL OUTCOMES OF PATIENTS TREATED WITH FRACTIONATED PHOTON RADIOTHERAPY FOR INTERMEDIATE AND HIGH-RISK MENINGIOMAS AT THE CHRISTIE HOSPITAL
Goyal, L.
Gaito, S.
France, A.
Colaco, R.
Mcbain, C.
Pan, S.
Whitfield, G.
NEURO-ONCOLOGY, 2023, 25
[23] EXPANDING INDICATIONS FOR THE USE OF CLASS-III AGENTS IN PATIENTS AT HIGH-RISK FOR SUDDEN-DEATH
SINGH, BN
JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 1995, 6 (10) : 887 - 900
[24] Adherence to, and outcomes of, a galactomannan screening protocol in high-risk hematology patients
Harricharan, S.
Biederman, K.
Bombassaro, A. M.
Lazo-Langner, A.
Elsayed, S.
Fulford, A.
Delport, J. A.
Xenocostas, A.
CURRENT ONCOLOGY, 2018, 25 (02) : E139 - E145
[25] Sex Specific Outcomes of TAVR with the Sapien 3 Valve: Insights From The PARTNER 2 S3 High-Risk and Intermediate-Risk Cohorts
Szerlip, Molly
Gualano, Sarah
Squiers, John
White, Jonathon
Doshi, Darshan
George, Isaac
Vazquez, Nicolas
Dimaio, John Michael
Makkar, Raj
Williams, Mathew
Herrmann, Howard
Svensson, Lars
Webb, John
Hahn, Rebecca
Kirtane, Ajay
Babaliaros, Vasilis
Thourani, Vinod
Alu, Maria
Kodali, Susheel
Leon, Martin
Mack, Michael
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 68 (18) : B272 - B273
[26] Optimal Mean Arterial Pressure Within 24 Hours of Admission for Patients With Intermediate-Risk and High-Risk Pulmonary Embolism
Chen, Jialong
Lin, Jing
Wu, Danshen
Guo, Xiaolan
Li, XiuHua
Shi, Songjing
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2020, 26
[27] EFFICACY AND SAFETY OF XIAOAIPING TABLETS IN THE TREATMENT OF ELDERLY PATIENTS WITH INTERMEDIATE-RISK/HIGH-RISK MYELODYSPLASTIC SYNDROME: A PILOT TRIAL
Sun, X.
Dai, X.
Xu, Z.
Li, D.
Zhu, X.
Li, L.
HAEMATOLOGICA, 2016, 101 : 776 - 776
[28] Bladder cancer: Confirmation of long-term superiority of adjuvant BCG in both intermediate-risk and high-risk patients
Drake R.
Nature Reviews Urology, 2010, 7 (4) : 177 - 177
[29] The role of PCA3 testing in a homogenenous population of patients with low and intermediate-risk prostate cancer treated with brachytherapy
Medina, Ana
Losada, Raquel
Marino, Alfonso
Candal Gomez, Arturo
Diaz, Inmaculada
Ramos Vazquez, Manuel
Luis Fernandez, Jose
Aranzazu Garcia, Sonia
Mendez, Carlos
Azpitarte, Cristina
Paris, Lorena
Chantada Abal, Venancio
Martinez Breijo, Sara
Anton Aparicio, Luis M.
Olmos, David
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[30] Outcomes of intermediate or high-risk CMML patients treated with hypomethylating agents combined with venetoclax: A single center experience
Li, Chao
Deng, Chengxin
Wu, Ping
Liu, Kaifan
Huang, Xin
Li, Mingmin
Chen, Xiaomei
Geng, Suxia
Lai, Peilong
Weng, Jianyu
Du, Xin
CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2024, 17 (01):

← 1 2 3 4 5 →